Fundamental Analysis of Calliditas Therapeutics - Growth / Value Index
CALT - Valuation Highlights
Valuation Analysis
Tsr Value Index - Poor Score of 31.25
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -2.98 | -2.62 | -118.43 % | |
| Price to Book | 1.93 | 3.53 | 447.49 % | 3.53 |
| Price to Sales | 0.604 | 0.997 | 62.16 % | |
| Enterprise Value to EBITDA Multiple | -3.23 | -2.57 | -3275.95 % |
CALT - Profitability Highlights
Profitability Analysis
Steady Growth in EPS for last four quarters
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -64.78 | -134.85 | -150.65 % | -5.49 |
| Return On Asset | -16.52 | -24.28 | -15.04 % | -0.988 |
| Net Profit Margin | -20.25 | -38.12 | 25.76 % | -4.07 |
| Operating Profit Margin | -11.99 | -30.33 | 42.28 % | 6.51 |
| EBITDA Margin | -11.99 | -38.12 | 22.88 % | 6.51 |
Highlights
| Market Cap | 590392 K |
| Enterprise Value | 568704 K |
| Price/Book TTM | 1.93 |
| Outstanding Share | 26836.00 K |
| Float/ Outstanding Share | 139.66% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 2.00 |
| Altman Z Score | -1.14 |
| Sloan Ratio | -0.120 |
| Peter Lynch Fair Value | 0 |
CALT - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Tsr Growth Index - Poor Score of 25.38
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 1467.10 M | 47.52 % | 0 % |
| Gross Profit | 1393.36 M | 44.52 % | 0 % |
| EBITDA | -175907.00 K | 13.76 % | 0 % |
| Net Profit | -297027.00 K | 9.52 % | 0 % |
| EPS | -7.38 | 54.22 % | NA |
CALT - Stability Highlights
Stability Analysis
Tsr Stability Index - Very Poor Score of 5.00
Altman Z Score of -1.14 suggest high risk
Company has high debt burden
Company is unable to generate enough free cash to support the business.
Interest Coverage of -5.96
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 2.84 | 201.20 % | 0.0374 |
| Cash Ratio | 2.39 | -37.73 % | |
| Quick Ratio | 3.08 | -28.84 % | 3.08 |
| Shareholders Equity | 18.01 | -54.10 % | |
| Debt to EBITDA | -2.11 | -15.69 % |
Historical Valuation Ratios of Calliditas Therapeutics
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Calliditas Therapeutics
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Calliditas Therapeutics
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Calliditas Therapeutics
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)